Roberto Pili

  • 11420 Citations
  • 53 h-Index
1987 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Publications

2012

A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer

Morris, M. J., Eisenberger, M. A., Pili, R., Denmeade, S. R., Rathkopf, D., Slovin, S. F., Farrelly, J., Chudow, J. J., Vincent, M., Scher, H. I. & Carducci, M. A., Oct 2012, In : Annals of Oncology. 23, 10, p. 2714-2719 6 p., mds078.

Research output: Contribution to journalArticle

27 Scopus citations

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

Bruce, J. Y., Eickhoff, J., Pili, R., Logan, T., Carducci, M., Arnott, J., Treston, A., Wilding, G. & Liu, G., Apr 2012, In : Investigational New Drugs. 30, 2, p. 794-802 9 p.

Research output: Contribution to journalArticle

51 Scopus citations

Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma

Keizman, D., Ish-Shalom, M., Pili, R., Hammers, H., Eisenberger, M. A., Sinibaldi, V., Boursi, B., Maimon, N., Gottfried, M., Hayat, H., Peer, A., Kovel, S., Sella, A., Berger, R. & Carducci, M. A., May 1 2012, In : European Journal of Cancer. 48, 7, p. 1031-1037 7 p.

Research output: Contribution to journalArticle

42 Scopus citations

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

Shen, L. & Pili, R., Dec 1 2012, In : OncoImmunology. 1, 6, p. 948-950 3 p.

Research output: Contribution to journalArticle

21 Scopus citations

Class I Histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models

Shen, L., Ciesielski, M., Ramakrishnan, S., Miles, K. M., Ellis, L., Sotomayor, P., Shrikant, P., Fenstermaker, R. & Pili, R., Jan 27 2012, In : PloS one. 7, 1, e30815.

Research output: Contribution to journalArticle

100 Scopus citations

Contrasting effects of sunitinib within in vivo models of metastasis

Welti, J. C., Powles, T., Foo, S., Gourlaouen, M., Preece, N., Foster, J., Frentzas, S., Bird, D., Sharpe, K., Weverwijk, A. V., Robertson, D., Soffe, J., Erler, J. T., Pili, R., Springer, C. J., Mather, S. J. & Reynolds, A. R., Jul 30 2012, In : Angiogenesis. 15, 4, p. 623-641 19 p.

Research output: Contribution to journalArticle

42 Scopus citations

Development of a castrate resistant transplant tumor model of prostate cancer

Ellis, L., Lehet, K., Ramakrishnan, S., Adelaiye, R. & Pili, R., May 1 2012, In : Prostate. 72, 6, p. 587-591 5 p.

Research output: Contribution to journalArticle

12 Scopus citations

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer

Tolcher, A. W., Chi, K. N., Shore, N. D., Pili, R., Molina, A., Acharya, M., Kheoh, T., Jiao, J. J., Gonzalez, M., Trinh, A., Pankras, C. & Tran, N., Aug 2012, In : Cancer Chemotherapy and Pharmacology. 70, 2, p. 305-313 9 p.

Research output: Contribution to journalArticle

22 Scopus citations

Epigenetic targeting and histone deacetylase inhibition in RCC

Ramakrishnan, S. & Pili, R., Nov 1 2012, Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets. Springer US, Vol. 9781461424000. p. 193-211 19 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mind the gap: Potential for rebounds during antiangiogenic treatment breaks

Ebos, J. M. L. & Pili, R., Jul 15 2012, In : Clinical Cancer Research. 18, 14, p. 3719-3721 3 p.

Research output: Contribution to journalArticle

12 Scopus citations

Modulation of chemotherapeutic efficacy by vascular disrupting agents: Optimizing the sequence and schedule

Wang, E. S., Pili, R. & Seshadri, M., Mar 1 2012, In : Journal of Clinical Oncology. 30, 7, p. 760-761 2 p.

Research output: Contribution to journalLetter

15 Scopus citations

Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells

Minelli, R., Cavalli, R., Ellis, L., Pettazzoni, P., Trotta, F., Ciamporcero, E., Barrera, G., Fantozzi, R., Dianzani, C. & Pili, R., Nov 20 2012, In : European Journal of Pharmaceutical Sciences. 47, 4, p. 686-694 9 p.

Research output: Contribution to journalArticle

43 Scopus citations

Phase i study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

Pili, R., Salumbides, B., Zhao, M., Altiok, S., Qian, D., Zwiebel, J., Carducci, M. A. & Rudek, M. A., Jan 3 2012, In : British Journal of Cancer. 106, 1, p. 77-84 8 p.

Research output: Contribution to journalArticle

103 Scopus citations

Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: Association with outcome and predictive nomogram

Keizman, D., Gottfried, M., Ish-Shalom, M., Maimon, N., Peer, A., Neumann, A., Rosenbaum, E., Kovel, S., Pili, R., Sinibaldi, V., Carducci, M. A., Hammers, H., Eisenberger, M. A. & Sella, A., Dec 31 2012, In : Oncologist. 17, 12, p. 1508-1514 7 p.

Research output: Contribution to journalArticle

64 Scopus citations

Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition

Chintala, S., Najrana, T., Toth, K., Cao, S., Durrani, F. A., Pili, R. & Rustum, Y. M., Jul 17 2012, In : BMC Cancer. 12, 293.

Research output: Contribution to journalArticle

38 Scopus citations

Testicular cancer

Motzer, R. J., Agarwal, N., Beard, C., Bhayani, S., Bolger, G. B., Buyyounouski, M. K., Carducci, M. A., Chang, S. S., Choueiri, T. K., Gupta, S., Hancock, S. L., Hudes, G. R., Jonasch, E., Kuzel, T. M., Lau, C., Levine, E. G., Lin, D. W., Margolin, K. A., Michaelson, M. D., Olencki, T. & 8 others, Pili, R., Ratliff, T. W., Redman, B. G., Robertson, C. N., Ryan, C. J., Sheinfeld, J., Wang, J. & Wilder, R. B., Apr 1 2012, In : JNCCN Journal of the National Comprehensive Cancer Network. 10, 4, p. 502-535 34 p.

Research output: Contribution to journalReview article

Open Access
54 Scopus citations

The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma

Keizman, D., Ish-Shalom, M., Huang, P., Eisenberger, M. A., Pili, R., Hammers, H. & Carducci, M. A., Jan 1 2012, In : European Journal of Cancer. 48, 2, p. 202-208 7 p.

Research output: Contribution to journalArticle

140 Scopus citations

Vascular disruption in combination with mTOR inhibition in renal cell carcinoma

Ellis, L., Shah, P., Hammers, H., Lehet, K., Sotomayor, P., Azabdaftari, G., Seshadri, M. & Pili, R., Feb 2012, In : Molecular cancer therapeutics. 11, 2, p. 383-392 10 p.

Research output: Contribution to journalArticle

15 Scopus citations
2013

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer

Pili, R., Qin, R., Flynn, P. J., Picus, J., Millward, M., Ho, W. M., Pitot, H., Tan, W., Miles, K. M., Erlichman, C. & Vaishampayan, U., Dec 1 2013, In : Clinical Genitourinary Cancer. 11, 4, p. 477-483 7 p.

Research output: Contribution to journalArticle

50 Scopus citations

Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer

Ellis, L., Ku, S. Y., Ramakrishnan, S., Lasorsa, E., Azabdaftari, G., Godoy, A. & Pili, R., Dec 2013, In : Oncotarget. 4, 12, p. 2225-2236 12 p.

Research output: Contribution to journalArticle

Open Access
49 Scopus citations

Dietary protein restriction inhibits tumor growth in human xenograft models of prostate and breast cancer

Fontana, L., Adelaiye, R. M., Rastelli, A. L., Miles, K. M., Ciamporcero, E., Longo, V. D., Nguyen, H., Vessella, R. & Pili, R., Dec 2013, In : Oncotarget. 4, 12, p. 2451-2461 11 p.

Research output: Contribution to journalArticle

Open Access
59 Scopus citations

Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma

Ramakrishnan, S. & Pili, R., Jul 1 2013, In : Cancer Journal (United States). 19, 4, p. 333-340 8 p.

Research output: Contribution to journalReview article

17 Scopus citations

Histone modifications: Implications in renal cell carcinoma

Ramakrishnan, S., Ellis, L. & Pili, R., Aug 2013, In : Epigenomics. 5, 4, p. 453-462 10 p.

Research output: Contribution to journalArticle

11 Scopus citations

Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer

Armstrong, A. J., Häggman, M., Stadler, W. M., Gingrich, J. R., Assikis, V., Polikoff, J., Damber, J. E., Belkoff, L., Nordle, Ö., Forsberg, G., Carducci, M. A. & Pili, R., Dec 15 2013, In : Clinical Cancer Research. 19, 24, p. 6891-6901 11 p.

Research output: Contribution to journalArticle

37 Scopus citations

Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer

Batty, N., Yarlagadda, N. & Pili, R., Aug 1 2013, In : JNCCN Journal of the National Comprehensive Cancer Network. 11, 8, p. 911-915 5 p.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations

Tasquinimod: A novel angiogenesis inhibitor-development in prostate cancer

George, S. & Pili, R., Apr 1 2013, In : Current oncology reports. 15, 2, p. 65-68 4 p.

Research output: Contribution to journalArticle

5 Scopus citations

Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancer

Rehman, S., Crane, A., Din, R., Raza, S. J., Shi, Y., Wilding, G., Levine, E. G., George, S., Pili, R., Trump, D. L. & Guru, K. A., Dec 1 2013, In : Urology. 82, 6, p. 1370-1375 6 p.

Research output: Contribution to journalArticle

29 Scopus citations

Use of a Glycolipid Inhibitor to Ameliorate Renal Cancer in a Mouse Model

Chatterjee, S., Alsaeedi, N., Hou, J., Bandaru, V. V. R., Wu, L., Halushka, M. K., Pili, R., Ndikuyeze, G. & Haughey, N. J., May 9 2013, In : PloS one. 8, 5, e63726.

Research output: Contribution to journalArticle

14 Scopus citations
2014

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature

Gotink, K. J., Broxterman, H. J., Honeywell, R. J., Dekker, H., de Haas, R. R., Miles, K. M., Adelaiye, R., Griffioen, A. W., Peters, G. J., Pili, R. & Verheul, H. M. W., 2014, In : Oncoscience. 1, 12, p. 844-853 10 p.

Research output: Contribution to journalArticle

21 Scopus citations

Active ageing and success: A brief history of conceptual models

Petretto, D. R., Pili, R., Gaviano, L., Matos López, C. & Zuddas, C., Nov 28 2014, (Accepted/In press) In : Revista Espanola de Geriatria y Gerontologia.

Research output: Contribution to journalArticle

9 Scopus citations

Active smokingmay negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treatedwith sunitinib

Keizman, D., Gottfried, M., Ish-Shalom, M., Maimon, N., Peer, A., Neumann, A., Hammers, H., Eisenberger, M. A., Sinibaldi, V., Pili, R., Hayat, H., Kovel, S., Sella, A., Boursi, B., Weitzen, R., Mermershtain, W., Rouvinov, K., Berger, R. & Carducci, M. A., Jan 22 2014, In : Oncologist. 19, 1, p. 51-60 10 p.

Research output: Contribution to journalArticle

35 Scopus citations

Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma

Buck, M. J., Raaijmakers, L. M., Ramakrishnan, S., Wang, D., Valiyaparambil, S., Liu, S., Nowak, N. J. & Pili, R., Oct 9 2014, In : Oncogene. 33, 41, p. 4961-4965 5 p.

Research output: Contribution to journalArticle

11 Scopus citations

An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer

Pili, R., Carducci, M., Brown, P. & Hurwitz, H., Dec 1 2014, In : Investigational New Drugs. 32, 6, p. 1258-1268 11 p.

Research output: Contribution to journalArticle

4 Scopus citations

Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)1A.J.A. and R.K. contributed equally to this work

Armstrong, A. J., Kaboteh, R., Carducci, M. A., Damber, J. E., Stadler, W. M., Hansen, M., Edenbrandt, L., Forsberg, G., Nordle, Ö., Pili, R. & Morris, M. J., 2014, In : Urologic Oncology: Seminars and Original Investigations. 32, 8, p. 1308-1316 9 p.

Research output: Contribution to journalArticle

35 Scopus citations

Cancer of the Kidney

Pili, R., Kauffman, E. & Rodriguez, R., Jan 1 2014, Abeloff's Clinical Oncology: Fifth Edition. Elsevier Inc., p. 1416-1444.e5

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations

Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells

Kato, Y., Yoshino, I., Egusa, C., Maeda, T., Pili, R. & Tsuboi, R., Aug 2014, In : Journal of Dermatological Science. 75, 2, p. 140-147 8 p.

Research output: Contribution to journalArticle

14 Scopus citations

Dll4 blockade potentiates the anti-tumor Effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts

Miles, K. M., Seshadri, M., Ciamporcero, E., Adelaiye, R., Gillard, B., Sotomayor, P., Attwood, K., Shen, L., Conroy, D., Kuhnert, F., Lalani, A. S., Thurston, G. & Pili, R., Nov 13 2014, In : PloS one. 9, 11, e112371.

Research output: Contribution to journalArticle

31 Scopus citations

Generation of a syngeneic orthotopic transplant model of prostate cancer metastasis

Ellis, L., Lehet, K., Ku, S. Y., Azabdaftari, G. & Pili, R., Jan 1 2014, In : Oncoscience. 1, 10, p. 609-613 5 p.

Research output: Contribution to journalArticle

9 Scopus citations

High-dose interleukin-2 therapy for metastatic renal cell carcinoma: A contemporary experience

Hanzly, M., Aboumohamed, A., Yarlagadda, N., Creighton, T., Digiorgio, L., Fredrick, A., Rao, G., Mehedint, D., George, S., Attwood, K., Kauffman, E., Narashima, D., Khushalani, N. I., Pili, R. & Schwaab, T., May 2014, In : Urology. 83, 5, p. 1129-1134 6 p.

Research output: Contribution to journalArticle

16 Scopus citations

Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer

Ku, S. Y., Lasorsa, E., Adelaiye, R., Ramakrishnan, S., Ellis, L. & Pili, R., Jul 29 2014, In : PloS one. 9, 7, e103680.

Research output: Contribution to journalArticle

7 Scopus citations

Kidney cancer, version 2.2014

Motzer, R. J., Jonasch, E., Agarwal, N., Beard, C., Bhayani, S., Bolger, G. B., Chang, S. S., Choueiri, T. K., Derweesh, I. H., Gupta, S., Hancock, S. L., Kim, J. J., Kuzel, T. M., Lam, E. T., Lau, C., Levine, E. G., Lin, D. W., Margolin, K. A., Michaelson, M. D., Olencki, T. & 12 others, Pili, R., Plimack, E. R., Rampersaud, E. N., Redman, B. G., Ryan, C. J., Sheinfeld, J., Sircar, K., Somer, B., Wang, J., Wilder, R. B., Dwyer, M. A. & Kumar, R., Feb 1 2014, In : JNCCN Journal of the National Comprehensive Cancer Network. 12, 2, p. 175-182 8 p.

Research output: Contribution to journalReview article

Open Access
44 Scopus citations

Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer

Gupta, N., Ustwani, O. A., Shen, L. & Pili, R., Feb 12 2014, In : OncoTargets and Therapy. 7, p. 223-234 12 p.

Research output: Contribution to journalArticle

16 Scopus citations

Mechanisms of action of tasquinimod on the tumour microenvironment

Raymond, E., Dalgleish, A., Damber, J. E., Smith, M. & Pili, R., Jan 2014, In : Cancer Chemotherapy and Pharmacology. 73, 1, p. 1-8 8 p.

Research output: Contribution to journalReview article

34 Scopus citations

Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy

Tracz, A., Mastri, M., Lee, C. R., Pili, R. & Ebos, J. M. L., Apr 29 2014, In : Journal of Visualized Experiments. 86, e51485.

Research output: Contribution to journalArticle

9 Scopus citations
2015

Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models

Ciamporcero, E., Miles, K. M., Adelaiye, R., Ramakrishnan, S., Shen, L., Ku, S. Y., Pizzimenti, S., Sennino, B., Barrera, G. & Pili, R., Jan 1 2015, In : Molecular cancer therapeutics. 14, 1, p. 101-110 10 p.

Research output: Contribution to journalArticle

58 Scopus citations

Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines

Motzer, R. J., Jonasch, E., Agarwal, N., Beard, C., Bhayani, S., Bolger, G. B., Chang, S. S., Choueiri, T. K., Costello, B. A., Derweesh, I. H., Gupta, S., Hancock, S. L., Kim, J. J., Kuzel, T. M., Lam, E. T., Lau, C., Levine, E. G., Lin, D. W., Michaelson, M. D., Olencki, T. & 12 others, Pili, R., Plimack, E. R., Rampersaud, E. N., Redman, B. G., Ryan, C. J., Sheinfeld, J., Shuch, B., Sircar, K., Somer, B., Wilder, R. B., Dwyer, M. & Kumar, R., Feb 1 2015, In : JNCCN Journal of the National Comprehensive Cancer Network. 13, 2, p. 151-159 9 p.

Research output: Contribution to journalReview article

Open Access
165 Scopus citations

Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer

Kalmuk, J., Folaron, M., Buchinger, J., Pili, R. & Seshadri, M., 2015, In : Oncotarget. 6, 27, p. 24376-24392 17 p.

Research output: Contribution to journalArticle

6 Scopus citations

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer

Weiss, A., Ding, X., van Beijnum, J. R., Wong, I., Wong, T. J., Berndsen, R. H., Dormond, O., Dallinga, M., Shen, L., Schlingemann, R. O., Pili, R., Ho, C. M., Dyson, P. J., van den Bergh, H., Griffioen, A. W. & Nowak-Sliwinska, P., Jul 20 2015, In : Angiogenesis. 18, 3, p. 233-244 12 p.

Research output: Contribution to journalArticle

64 Scopus citations

Restriction of dietary protein decreases mTORC1 in tumors and somatic tissues of a tumor-bearing mouse xenograft model

Lamming, D. W., Cummings, N. E., Rastelli, A. L., Gao, F., Cava, E., Bertozzi, B., Spelta, F., Pili, R. & Fontana, L., 2015, In : Oncotarget. 6, 31, p. 31233-31240 8 p.

Research output: Contribution to journalArticle

23 Scopus citations

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications

Adelaiye, R., Ciamporcero, E., Miles, K. M., Sotomayor, P., Bard, J., Tsompana, M., Conroy, D., Shen, L., Ramakrishnan, S., Ku, S. Y., Orillion, A., Prey, J., Fetterly, G., Buck, M., Chintala, S., Bjarnasone, G. A. & Pili, R., Feb 1 2015, In : Molecular cancer therapeutics. 14, 2, p. 513-522 10 p.

Research output: Contribution to journalArticle

39 Scopus citations